WHO Must Overhaul Biosimilar Approval Guidelines
Civil Society Groups Call On WHO To Update Guidance
Civil society groups from around the world are pushing the World Health Organization to update its guidelines for approving biosimilars in order to make them affordable and accessible for patients, especially those in poorer countries.
You may also be interested in...
A team of researchers has concluded that in vivo animal studies and large safety and efficacy studies are rarely necessary to license biosimilars.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.
Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.